Although in the present study we did not inhibit MCT1 in vivo, targeting MCT1 and CAII together may synergistically increase the therapeutic benefits of their inhibitors through decreasing cancer cell proliferation and inhibiting tumor angiogenesis, which supports tumor growth and metastasis. Here, SLC16A1 is linked to cancer.